CADENCE PHARMACEUTICALS INC·4

Mar 21, 1:43 PM ET

CADENCE PHARMACEUTICALS INC 4

4 · CADENCE PHARMACEUTICALS INC · Filed Mar 21, 2014

Insider Transaction Report

Form 4
Period: 2014-03-19
FRAZIER ALAN D
Director10% Owner
Transactions
  • Disposition from Tender

    common stock

    2014-03-19$14.00/sh3,816,474$53,430,6360 total(indirect: By Frazier Healthcare VI, L.P.)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$10.80/sh15,000$162,0000 total
    Exercise: $3.20Exp: 2016-07-12common stock (15,000 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$6.84/sh12,500$85,5000 total
    Exercise: $7.16Exp: 2020-06-16common stock (12,500 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$11.02/sh17,500$192,8500 total
    Exercise: $2.98Exp: 2022-06-13common stock (17,500 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$6.79/sh25,000$169,7500 total
    Exercise: $7.21Exp: 2023-06-12common stock (25,000 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$12.64/sh10,000$126,4000 total
    Exercise: $1.36Exp: 2016-05-08common stock (10,000 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$1.70/sh12,500$21,2500 total
    Exercise: $12.30Exp: 2017-06-27common stock (12,500 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$4.63/sh12,500$57,8750 total
    Exercise: $9.37Exp: 2019-06-23common stock (12,500 underlying)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$4.75/sh12,500$59,3750 total
    Exercise: $9.25Exp: 2021-06-15common stock (12,500 underlying)
  • Disposition from Tender

    common stock

    2014-03-19$14.00/sh4,796,711$67,153,9540 total(indirect: By Frazier Healthcare V, L.P.)
  • Disposition to Issuer

    stock option (right to buy)

    2014-03-19$7.65/sh12,500$95,6250 total
    Exercise: $6.35Exp: 2018-06-17common stock (12,500 underlying)
Footnotes (3)
  • [F1]The general partner of Frazier Healthcare VI, LP is FHM VI, LP. FHM VI, LLC is the general partner of FHM VI, LP. Mr. Frazier is a managing member of FHM VI, LLC. Mr. Frazier disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein and this report shall not be deemed an admission for Section 16 or any other purpose.
  • [F2]The general partner of Frazier Healthcare V, LP is FHM V, LP. FHM V, LLC is the general partner of FHM V, LP. Mr. Frazier is a managing member of FHM V, LLC. Mr. Frazier disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein and this report shall not be deemed an admission for Section 16 or any other purpose.
  • [F3]In connection with the merger of Cadence Pharmaceuticals, Inc. ("Cadence") with Madison Merger Sub, Inc. ("Merger Sub") on March 19, 2014, and pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") by and among Cadence, Mallinckrodt plc ("Parent") and Merger Sub, dated February 10, 2014, this option became fully vested and was automatically canceled and terminated and the holder became entitled to receive an amount in cash, without interest and less the amount of any tax withholding, equal to the product of (a) the number of shares of common stock of Cadence underlying such option multiplied by (b) the excess, if any, of $14.00 (the "Offer Price") over the exercise price per share of such option.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION